Ajooni Biotech Limited — Important, 09-01-2025: Updates

**Financial Highlights:** In Q2 FY25, Ajooni Biotech reported net sales of ₹25.72 crore, up from ₹19.48 crore YoY, contributing to a total income of ₹26.03 crore, reflecting a growth of 31.69%. The company's operating expenses increased to ₹24.95 crore but still resulted in an EBITDA of ₹1.08 crore, marking a 16.54% increase in profitability. For H1 FY25, net sales rose to ₹51.38 crore from ₹40.48 crore, with a total income growth of 26.65%, leading to a net profit surge of approximately 58.59% to ₹1.28 crore.

**Strategic Initiatives and Growth Drivers:** A significant repeat export order from Avon Animal Health highlights Ajooni's strong foothold in the Bangladesh market. Participation in major agro expos and signing an MOU with UAMMCL for expanding its cattle feed business across five states positions the company for positive growth.

**Business Developments:** The company has secured another repeat order from a top dairy supplier valued at ₹4.95 crore, indicating a strong demand for its pure veg cattle feed. It has also successfully entered the Gujarat market, diversifying its geographic presence.

**Market Position and Competitive Advantage:** Ajooni, recognized for its commitment to quality and innovation in pure veg animal health solutions, holds a competitive edge over a limited number of organized players in India. The company recently received BIS certification and ISI mark for its mineral mixture, strengthening its market credibility.

**Investor Implications:** The combination of strong quarterly performance, strategic partnerships, and expanded market presence suggests a positive outlook for Ajooni Biotech. As the demand for high-quality animal feed grows, this positions the company as a potentially lucrative investment opportunity.